All News
Predictive Risk Factors for Uveitis in JIA
Researchers from Germany have studied a large cohort of juvenile idiopathic arthritis (JIA) patients and shown that JIA disease activity scores and laboratory biomarkers could be used to better define the group of JIA patients at high risk of uveitis onset.
Read ArticleHydroxychloroquine Being Over-Dosed with New Guidelines?
Hydroxychloroquine retinopathy prevention guidelines have revised from ideal body weight-based dosing to actual body weight-based dosing; the question remains whether these have been adopted in clinical practice.
A database of nearly 21,000 new HCQ users from a UK general population database studied HCQ dosing and use between 2007 and 2016. Specifically they examined whether users were subjected to excess HCQ dosing per ophthalmology guidelines (defined by exceeding 6.5 mg/kg of IBW and 5.0 mg/kg of ABW).
Best of 2017: New EULAR Guidelines on Behçet's
At the EULAR 2016 meeting, new EULAR recommendations for the management of Behçet's disease (BD) were presented.
Read ArticleCanada Closer to Marijuana Approval
Reuters reports that Canada’s Senate on Thursday voted to legalize recreational marijuana, clearing a major hurdle that puts the country on track to become the first Group of Seven nation to permit national use of the drug.
Read ArticleFish Oil Fails in Dry Eye Trial
Many topical and OTC products are recommended when treating chronic dry eyes, including omega-3 fatty acids (fish oil or n−3 fatty acids) to relieve symptoms; the NEJM reports that the DREAM trial shows no clinical benefit of n−3 fatty acids for 12 months when compared to placebo.
Read ArticleUveitis in JIA: Screen All, Treat Early
A European group of experts has formulated consensus-based recommendations for the treatment of juvenile idiopathic arthritis (JIA)-associated uveitis, focusing on screening, monitoring, and treatment of this potentially devastating extra-articular manifestation of JIA.
Read ArticleThe RWCS - RheumNow Week in Review - 9 February 2018
Dr. Jack Cush reviews highlights, news and recent research published this week on RheumNow.com. This week's report includes news and education from the RWCS meeting in Maui.
Read ArticleRecurrent Uveitis Increases the Risk of Ankylosing Spondylitis
Arthritis Research and Therapy reports on the epidemiologic association between recurrent anterior uveitis and ankylosing spondylitis (AS) noting that as the number of uveitis episodes increases, so does the incidence of AS.
Read ArticleThe RheumNow Week in Review - 2 February 2018
Dr. Jack Cush reviews highlights, news and recent research published this week on RheumNow.com. This week's report includes rising epidemiologic numbers, vaccine updates for H.
Read ArticleThe Red Eye in the Rheumatology Patient
Professor Rosenbaum is well known for his expertise in rheumatic eye disease and he gave a great summary of how to approach your patient having a red eye.
Key Takeaways from ACR Review Course
The ACR Review Course was superb once again from top to bottom, from Blue Fingers to Practical Treatment of RA. Every year I wonder if I should skip it, but each year I go. And I have never regretted it. Here are my take-home messages and “pearls” from the ACR Review Course.
Read ArticleAbbvie's Robust ACR Presentations
AbbVie announced that data from 38 abstracts of HUMIRA® (adalimumab) and the company's portfolio of investigational immunology medicines will be presented at the 2017 American College of Rheumatology (ACR)/Association for Rheumatology Health Professionals (ARHP) Annual Meeting, November 3-8, in S
Read ArticleUveitis Events Reduced with Select TNF Inhibitors
Uveitis may occur in up to 40% of spondyloarthritis patients. Metanalyses have shown that treatment with tumour necrosis factor-α inhibitor may reduce the rates of anterior uveitis. A multicenter study from Sweden and Norway has confirmed that amongst TNFi, adalimumab and infliximab offer better protection against AU than etanercept.
Read ArticlePediatric Consensus on Comorbidity Assessments
Comorbidity is a serious consequence or confounder in patients with inflammatory diseases. This has been well described in both psoriatic and rheumatoid disease.
Read ArticleNEJM: Adalimumab and MTX Effective in JIA Uveitis
The NEJM has published the results of a randomized, placebo-controlled trial showing adalimumab and methotrexate is effective in reducing ocular flares in juvenile idiopathic arthritis with uveitis.
Read ArticleInconsistent ESR & CRP in Spondylitis Patients
Patients with active axial spondyloarthritis (axSpA) can lack evidence of inflammation on magnetic resonance imaging (MRI) but may develop evidence of inflammation over time.
Read ArticleThe RheumNow Week in Review – 10 March 2017
Dr. Jack Cush reviews news and highlights from the past week on RheumNow.com. Sign up at RheumNow.com to received daily or weekly news, blogs and tweets on all things rheumatology
Read ArticleTNF Inhibitor Therapy and the Risk of Anterior Uveitis Recurrence
The TNF inhibitor drug development trials have indirectly taught us that monoclonal antibody based TNFi was capable of retarding the recurrence of anterior uveitis (AU) in patients with ankylosing spondylitis (AS).
Read ArticleRheumNow Week in Review – 14 October 2015
Dr Jack Cush reviews highlights from the news and journal articles appearing this week on RheumNow.com:
Read ArticleMy Take on New Ocular Screening Guidelines for Plaquenil
A recent article published by the American Academy of Ophthalmology presented new recommendations for screening of patients being managed with hydroxychloroquine that changed the previous monitoring paradigm. More importantly, it has repositioned hydroxychloroquine from one of the safest medications that rheumatologists use to a drug that can have potentially significant ocular morbidity (if used in doses greater than 5 mg per kilogram and or for prolonged periods of time).